Skip to content
Book a SimplyMerit Demo

Parker Institute for Cancer Immunotherapy: Ensuring Fair and Competitive Executive Compensation

cancer_2000_

Industry

Nonprofit/Charity

Challenge

PICI required a robust, defensible approach to executive compensation that would align with IRS reasonableness standards, ensure competitiveness across both nonprofit and biopharma sectors, and withstand governance scrutiny. The organization needed to synthesize data from diverse sources, normalize for fiscal year differences, and benchmark against relevant peer organizations to validate total cash and base pay levels for its top executives.

Results

MorganHR's audit confirmed that compensation for five out of six PICI executives was within a reasonable and defendable market range, with comprehensive analysis supporting the organization's approach even where individual roles exceeded market averages. The findings validated the use of for-profit biopharma comparators and provided the Board with actionable documentation, reinforcing best practices in executive pay governance and supporting ongoing regulatory compliance.

Key Product: Compensation Consulting

5 of 6
Executives Within Market Range
3
Independent Data Sources Validated
4.5%
Annual Market Aging
4
Regression Models Conducted

COLLECT TESTIMONIAL FROM KEVIN MARKS

Kevin Marks

Chief Legal Officer

download (11)

About your Customer

The Parker Institute for Cancer Immunotherapy (PICI) is a San Francisco–based nonprofit organization founded in 2016 by Sean Parker. PICI funds and accelerates the development of breakthrough immune therapies to turn all cancers into curable diseases, uniting top researchers from leading academic and medical institutions in a collaborative network to drive innovation in cancer immunotherapy.

The Challenge

As a leader in cancer immunotherapy research, PICI faced increasing complexity in managing executive compensation due to the intersection of nonprofit and biopharma talent markets. With heightened regulatory expectations and the need to attract and retain specialized leadership, PICI sought an independent assessment to confirm that its pay practices were not only competitive but also met IRS and industry governance standards. Ensuring transparent, data-driven compensation decisions was essential to maintain stakeholder trust and organizational credibility.

The Solution

PICI engaged MorganHR to conduct a comprehensive Executive Compensation Audit. MorganHR applied a multi-faceted methodology, analyzing IRS Form 990 data, Radford biopharma surveys, and Economic Research Institute (ERI) benchmarks. Market data was aged to the current fiscal year and normalized using regression models for variables such as assets, revenue, expenses, and staff size. MorganHR's thorough process was designed to deliver actionable insights and support defensible, compliant decision-making. According to Kevin Marks, Chief Legal Counsel at PICI, "MorganHR’s rigorous methodology provided us with the assurance and transparency we needed to demonstrate responsible executive compensation governance to our Board and stakeholders."

The Results

The audit demonstrated that five out of six executive roles were within a reasonable market range, with the Chief Medical Officer’s total compensation remaining defensible relative to biopharma peers despite above-market cash compensation. The approach validated PICI’s rationale for using for-profit comparators and reinforced best-in-class governance practices. Key metrics from the audit included the use of three independent market data sources, a 4.5% annual market aging adjustment, and four regression model validations. The Board received clear, robust documentation supporting compliance and transparency for future governance reviews and regulatory filings.

Ready to get started?

Call to action